Table 4 Univariate and Multivariable Analysis of Factors Associated with TBI Treatment Completion

 No Comorbidity (Score = 0)

ref

 Any Comorbidity (Score ≥ 1)

1.10

[0.77,1.56]

 No

ref

ref

 Yes

5.46

[1.57,18.94]

7.27

[1.93,27.30]

 No

ref

 Yes

1.29

[0.84,1.19]

 No

ref

 Yes

1.05

[0.50,2.21]

 No

ref

 Yes

0.73

[0.16,3.28]

 Tuberculin Skin Test

ref

 Interferon Gamma Release Assay

1.21

[0.80,1.84]

 2012

ref

 2013

1.50

[0.93,2.41]

 2014

1.32

[0.79,2.18]

 2015

1.12

[0.66,1.89]

 2016

0.99

[0.58,1.70]

 Single

ref

ref

 Family of 2–3

1.36

[0.89,2.07]

1.18

[0.74,1.87]

 Family of > 3

1.05

[0.71,1.56]

1.11

[0.70,1.74]

 Female

ref

ref

 Male

1.01

[0.72,1.43]

1.02

[0.74,1.49]

 Sub-Saharan Africa

ref

ref

 South-eastern Asia

2.10

[1.34,3.29]

2.30

[1.43,3.70]

 Southern Asia

1.63

[1.05,2.58]

1.64

[1.02,2.64]

 Western Asia

0.88

[0.44,1.77]

0.64

[0.29,1.38]

 Other

2.00

[0.84,4.79]

2.33

[0.92,5.94]

 No

ref

 Yes

0.92

[0.47,1.79]

 No

ref

ref

 Yes

1.51

[1.08,2.12]

1.65

[1.14,2.40]

 9H: Isoniazid only

ref

ref

 3HP: Isoniazid + Rifapentine

1.33

[.087,2.04]

1.58

[0.99,2.51]

 4R: Rifampin

1.49

[0.47,4.79]

1.47

[0.42,5.10]

 Multiple regimens

1.65

[0.75,3.61]

1.54

[0.68,3.47]

 Screened after 11 vs 28 days

0.49

[0.28,0.86]

0.47

[0.26,0.86]

 Screened after 14 vs 28 days

0.61

[0.41,0.91]

0.48

[0.27,0.86]

Distance to TB Clinic, miles

0.92

[0.82,1.03]

Age^b

1.00

[0.99,1.01]

1.00

[0.99,1.02]